文献速递前列腺癌

前列腺癌男性分层癌症主动监测项目的5年结果

The 5-year results of the Stratified Cancer Active Surveillance programme for men with prostate cancer.
PubMed 文献 · BJU Int · 2025-01-29

STRATCANS项目根据诊断时的NICE CPG分级、前列腺特异抗原密度和MRI可见性对CPG1和CPG2前列腺癌主动监测患者进行风险分层并分配三种随访强度。297名男性中位随访4.9年,72.1%未接受治疗,仅11.7%因进展至CPG≥3而治疗,无癌死亡或转移事件,STRATCANS分层预测CPG≥3进展的AUC为0.74。

要点

  • 297名CPG1/CPG2主动监测男性,中位随访4.9年,72.1%未治疗,无癌死亡或转移。
  • 因CPG≥3进展而治疗者占11.7%,CPG1为7.6%、CPG2为18.5%。
  • STRATCANS分层预测CPG≥3进展AUC 0.74,优于GG、CPG、Likert评分单独或联合。

核心结论

  • STRATCANS 5年结局表明,使用具有预后意义的终点进行简单风险分层监测是安全、持久的,治疗率低、患者依从性高,并根据进展风险适当调整监测强度。
  • 网站和实施工具包现已可用。

研究设计与样本

  • STRATCANS项目纳入选择主动监测的CPG1和CPG2前列腺癌男性,根据诊断时NICE CPG、前列腺特异抗原密度和MRI可见性分配至三种递增随访强度。
  • 共回顾297名男性,中位年龄66.0岁;仍在主动监测者的中位(四分位距,均值)随访为4.9(2.7-7.6,5.3)年。
  • 队列中38.0%为CPG2,25.0%在主动监测入组时为Grade Group(GG)2。

主要发现

  • 214/297(72.1%)未接受治疗:158(53.1%)仍在主动监测,17(5.7%)死于其他原因,39(13.1%)进展至观察等待或出院。
  • 仅10(3.4%)因焦虑离开主动监测;无癌死亡或转移事件。
  • 80名男性(26.9%)因活检/MRI进展转为治疗,但其中仅35名(11.7%)达到CPG≥3疾病。
  • 因CPG≥3进展而治疗在CPG1为7.6%、CPG2为18.5%,在GG1为9.9%、GG2为17.5%。
  • 按STRATCANS分层,因CPG≥3进展而治疗在STRATCANS 1为4.7%、STRATCANS 2为12.9%、STRATCANS 3为27.4%(P < 0.001)。

临床怎么用

  • 作者指出,纵向数据已允许进一步细化STRATCANS方案。
  • 作者指出,网站和实施工具包现已可用。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To report 5-year outcomes from the STRATified CANcer Surveillance (STRATCANS) programme based on progression risks using National Institute for Health and Clinical Excellence (NICE) Cambridge Prognostic Group (CPG) at diagnosis, prostate specific antigen density and magnetic resonance imaging (MRI) visibility. PATIENTS AND METHODS: Men with CPG1 and CPG2 disease selecting active surveillance (AS) were included into STRATCANS and allocated to one of three increasing follow-up intensities. Outcome measures were: (i) treatment for CPG≥3 progression (main outcome), (ii) any treatment, (iii) conversion to watchful waiting (WW), (iv) patient self-attrition, and (v) mortality. RESULTS: A total of 297 men (median age 66.0 years) were reviewed. The median (interquartile range, mean) follow-up for men still on AS was 4.9 (2.7-7.6, 5.3) years. In the cohort, 38.0% were CPG2 and 25.0% Grade Group (GG) 2 at AS entry. Overall, 214/297 (72.1%) remained treatment free: 158 (53.1%) were still on AS, 17 (5.7%) died of other causes, and 39 (13.1%) progressed to WW/discharge. Only 10 (3.4%) left AS from anxiety. There were no cancer deaths or metastatic events. In all, 80 men (26.9%) converted to treatment due to biopsy/MRI progression but only 35 (11.7%) of these reached CPG≥3 disease. Treatment for CPG≥3 occurred in 7.6% of CPG1 and 18.5% of CPG2 disease and 9.9% of GG1 and 17.5% of GG2 disease. By STRATCANS tier, treatment for CPG≥3 disease was 4.7% in STRATCANS 1, 12.9% in STRATCANS 2, and 27.4% in STRATCANS 3 (P < 0.001). STRATCANS had an area under the curve (AUC) of 0.74 for predicting CPG≥3 progression out-performing stratification by GG (AUC 0.64), CPG (0.69) and Likert score (0.51) alone or a combination of MRI visibility and GG (0.64). Longitudinal data have allowed further refinement of the STRATCANS schedule. CONCLUSIONS: The STRATCANS 5-year outcomes demonstrate that a simple risk stratified surveillance using a prognostically meaningful endpoint is safe, durable, has low treatment rates, high patient compliance and appropriately tailors monitoring based on risks of progression. A website and implementation toolkit are now available.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Gnanapragasam VJ, Keates A, Lophatananon A, et al. The 5-year results of the Stratified Cancer Active Surveillance programme for men with prostate cancer. BJU Int. 2025. PMID: 39888260. doi:10.1111/bju.16666

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。